利妥昔单抗-CHOP联合早期利妥昔单抗强化治疗弥漫大B细胞淋巴瘤:HOVON与北欧淋巴瘤组的随机III期试验(HOVON-84)
该随机III期试验纳入574例18至80岁弥漫大B细胞淋巴瘤患者,比较标准R-CHOP-14与在最初4个周期强化利妥昔单抗的RR-CHOP-14。诱导完全缓解率R-CHOP-14组为89%、RR-CHOP-14组为86%,差异无统计学意义;中位随访92个月,3年无失败生存、无进展生存和总生存两组均无显著差异。结论认为早期利妥昔单抗强化并未改善初治弥漫大B细胞淋巴瘤患者的结局。
要点
- 574例初治DLBCL患者随机接受R-CHOP-14或前4周期强化利妥昔单抗的RR-CHOP-14。
- 诱导完全缓解率R-CHOP-14组89% vs RR-CHOP-14组86%,HR 0.82(95%CI 0.50–1.36,P=.44)。
- 66至80岁患者在RR-CHOP-14组前4周期毒性显著更多,尤其是中性粒细胞减少和感染。
核心结论
- 在R-CHOP-14治疗初治弥漫大B细胞淋巴瘤时,早期强化利妥昔单抗未改善患者结局。
研究设计与样本
- HOVON与北欧淋巴瘤组开展的随机III期试验,共574例18至80岁弥漫大B细胞淋巴瘤患者。
- 患者随机接受6或8周期R-CHOP-14诱导治疗,分为前4周期强化利妥昔单抗组(RR-CHOP-14)与未强化组(R-CHOP-14)。
- 主要终点为诱导治疗后的完全缓解,分析按意向治疗进行。
主要发现
- 完全缓解:R-CHOP-14组254/286例(89%)vs RR-CHOP-14组249/288例(86%),HR 0.82(95%CI 0.50–1.36,P=.44)。
- 中位随访92个月(范围1–131个月),3年无失败生存:R-CHOP-14组74%(95%CI 68%–78%)vs RR-CHOP-14组69%(95%CI 63%–74%),HR 1.26(95%CI 0.98–1.61,P=.07)。
- 3年无进展生存:R-CHOP-14组74%(95%CI 69%–79%)vs RR-CHOP-14组71%(95%CI 66%–76%),HR 1.20(95%CI 0.94–1.55,P=.15)。
- 3年总生存:R-CHOP-14组81%(95%CI 76%–85%)vs RR-CHOP-14组76%(95%CI 70%–80%),HR 1.27(95%CI 0.97–1.67,P=.09)。
- 66至80岁患者在RR-CHOP-14组前4周期经历的毒性显著更多,尤其是中性粒细胞减少和感染。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab intensification during the first 4 cycles of R-CHOP could improve the outcome of these patients compared with standard R-CHOP. PATIENTS AND METHODS: A total of 574 patients with DLBCL age 18 to 80 years were randomly assigned to induction therapy with 6 or 8 cycles of R-CHOP-14 with (RR-CHOP-14) or without (R-CHOP-14) intensification of rituximab in the first 4 cycles. The primary end point was complete remission (CR) on induction. Analyses were performed by intention to treat. RESULTS: CR was achieved in 254 (89%) of 286 patients in the R-CHOP-14 arm and 249 (86%) of 288 patients in the RR-CHOP-14 arm (hazard ratio [HR], 0.82; 95% CI, 0.50 to 1.36; P = .44). After a median follow-up of 92 months (range, 1-131 months), 3-year failure-free survival was 74% (95% CI, 68% to 78%) in the R-CHOP-14 arm versus 69% (95% CI, 63% to 74%) in the RR-CHOP-14 arm (HR, 1.26; 95% CI, 0.98 to 1.61; P = .07). Progression-free survival at 3 years was 74% (95% CI, 69% to 79%) in the R-CHOP-14 arm versus 71% (95% CI, 66% to 76%) in the RR-CHOP-14 arm (HR, 1.20; 95% CI, 0.94 to 1.55; P = .15). Overall survival at 3 years was 81% (95% CI, 76% to 85%) in the R-CHOP-14 arm versus 76% (95% CI, 70% to 80%) in the RR-CHOP-14 arm (HR, 1.27; 95% CI, 0.97 to 1.67; P = .09). Patients between ages 66 and 80 years experienced significantly more toxicity during the first 4 cycles in the RR-CHOP-14 arm, especially neutropenia and infections. CONCLUSION: Early rituximab intensification during R-CHOP-14 does not improve outcome in patients with untreated DLBCL.
引用
- Lugtenburg PJ, de Nully Brown P, van der Holt B, et al. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). J Clin Oncol. 2020. PMID: 32730183. doi:10.1200/JCO.19.03418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。